Krystal Biotech Inc. | Mid-cap | Healthcare
$139.74
-2.33%
| Krystal Biotech Stock Comparison:
Krystal Biotech vs VertexKrystal Biotech vs RegeneronKrystal Biotech vs Blueprint MedicinesKrystal Biotech vs Roivant SciencesKrystal Biotech vs Bio-TechneKrystal Biotech vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 290.5M
Gross Profit 270.5M 93.09%
Operating Income 103.2M 35.52%
Net Income 89.2M 30.69%
EPS (Diluted) $3.00

Balance Sheet Metrics

Total Assets 1.1B
Total Liabilities 109.5M
Shareholders Equity 946.4M
Debt to Equity 0.12

Cash Flow Metrics

Operating Cash Flow 72.6M
Free Cash Flow 119.2M

Revenue & Profitability Trend

Krystal Biotech Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue290.5M50.7M000
Cost of Goods Sold20.1M3.1M00-
Gross Profit270.5M47.6M00-
Operating Expenses167.3M144.8M120.2M68.3M33.0M
Operating Income103.2M-97.2M-120.2M-68.3M-33.0M
Pre-tax Income95.4M12.9M-140.0M-69.6M-32.2M
Income Tax6.2M2.0M00-
Net Income89.2M10.9M-140.0M-69.6M-32.2M
EPS (Diluted)$3.00$0.39-$5.49-$3.13-$1.71

Income Statement Trend

Krystal Biotech Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets742.0M587.9M383.8M442.3M275.1M
Non-Current Assets313.8M230.4M174.7M184.0M35.8M
Total Assets1.1B818.4M558.4M626.3M310.8M
Liabilities
Current Liabilities102.0M33.1M28.8M25.7M15.5M
Non-Current Liabilities7.5M6.6M7.4M7.0M3.3M
Total Liabilities109.5M39.7M36.2M32.7M18.8M
Equity
Total Shareholders Equity946.4M778.6M522.2M593.6M292.1M

Balance Sheet Composition

Krystal Biotech Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income89.2M10.9M-140.0M-69.6M-32.2M
Operating Cash Flow72.6M7.9M-106.3M-50.9M-27.4M
Investing Activities
Capital Expenditures-4.2M-11.8M-53.0M-68.3M-14.8M
Investing Cash Flow-163.4M82.6M-114.1M-226.8M-11.2M
Financing Activities
Dividends Paid-----
Financing Cash Flow-5.4M202.8M35.3M347.7M118.0M
Free Cash Flow119.2M-100.6M-153.5M-116.3M-40.9M

Cash Flow Trend

Krystal Biotech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 33.07
Forward P/E 23.58
Price to Book 4.05
Price to Sales 11.95
PEG Ratio 23.58

Profitability Ratios

Profit Margin 37.18%
Operating Margin 41.03%
Return on Equity 13.90%
Return on Assets 8.66%

Financial Health

Current Ratio 9.65
Debt to Equity 0.98
Beta 0.66

Per Share Data

EPS (TTM) $4.17
Book Value per Share $34.07
Revenue per Share $11.61

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
krys4.0B33.074.0513.90%37.18%0.98
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.0024.19-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.